Jason Herpel

Jason Herpel has extensive work experience in the legal field. Jason is currently working at EyePoint Pharmaceuticals as the Vice President & Counsel for Securities, Corporate Governance & Strategic Transactions. Prior to this, they served as a Board Observer at NewPace Ltd. starting from December 2020 until May 2022.

From 2014 to 2022, Jason held various roles at BioTelemetry, Inc., including Vice President of Mergers & Acquisitions, Counsel, and Director & Associate General Counsel. During their tenure at BioTelemetry, Inc., they played a key role in leading numerous acquisitions and complex commercial transactions, which significantly contributed to the company's revenue growth from $25 million in 2014 to over $439 million. Jason was also responsible for formulating and executing the company's M&A strategy, presenting acquisition proposals to the CEO and Board of Directors, and managing the transaction process from start to finish. Additionally, they oversaw the integration phase and coordinated cross-functional teams.

Before joining BioTelemetry, Inc., Jason worked at Willis in the Life Sciences Group from 2010 to 2014 and at Weber Gallagher Simpson Stapleton Fires & Newby LLP as an Associate from 2005 to 2010. Jason began their legal career as an Assistant District Attorney at the Philadelphia District Attorney's Office, a role they held from 2003 to 2005.

Jason Herpel earned a B.A. degree in Journalism/American History from Penn State University between the years 1995 to 1999. Jason then pursued a J.D. degree at Penn State Dickinson Law from 2000 to 2003. Later, from 2016 to 2018, Jason pursued a Masters of Law (LL.M) degree specializing in Mergers & Acquisitions, Securities & Financial Regulation at Georgetown University Law Center. Before attending college, they likely attended Archbishop Ryan, although no specific years or degrees were provided for this education.